Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.
Type:
Grant
Filed:
October 4, 2021
Date of Patent:
December 5, 2023
Assignee:
Novartis AG
Inventors:
Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Fupeng Ma, Nathaniel F. Ware
Abstract: The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.
Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
Type:
Grant
Filed:
October 28, 2022
Date of Patent:
November 28, 2023
Assignee:
DERMAVANT SCIENCES GMBH
Inventors:
Channa K. Jayawickreme, Susan H. Smith, Cunyu Zhang, William Zuercher
Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.
Type:
Grant
Filed:
April 14, 2021
Date of Patent:
November 28, 2023
Assignee:
ECOLAB USA INC.
Inventors:
Junzhong Li, Richard K. Staub, David D. McSherry, Keith G. LaScotte, Steven J. Lange, Frank Everts
Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
May 18, 2022
Date of Patent:
November 14, 2023
Assignee:
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Abstract: Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
Type:
Grant
Filed:
July 19, 2021
Date of Patent:
November 14, 2023
Assignees:
ANNEXON, INC., APTUIT (VERONA) SRL
Inventors:
Dean R. Artis, Colin P. Leslie, Luca B. Mileo, Claudia Beato, Federico Sorana, Bruno Di Guglielmo, Chiara Padroni
Abstract: The integrated processes herein provide improved carbon efficiency for processes based on coal or biomass gasification or steam methane reforming. Provided are also ethylene oxide carbonylation products such as beta-propiolactone and succinic anhydride having a bio-based content between 0% and 100%, and methods for producing and analyzing the same.
Abstract: A gel composition for treating bowel diseases comprising about 0.1 to about 2.5 wt. % of an anti-epileptic agent; about 0.8 to about 2.0% wt. % of a collagen complexed with a date palm extract of Khalas cultivar and carboxymethylcellulose; about 10 to about 50 ?g/mL of vanillic acid; about 0.1 to about 0.3 ?g of stearic acid; and water; wherein all wt. % are based on g/100 g of the gel composition. This gel composition can be topically administered to the rectum of a patient to treat one or more bowel diseases, disorders, or conditions.
Type:
Grant
Filed:
February 24, 2023
Date of Patent:
November 7, 2023
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Ezzat Khalil Ahmed, Hairul Islam Mohamed Ibrahim, Krishnaraj Thirugnanasambantham
Abstract: Compositions for topical application that effectively deliver antioxidants across the epidermis, dermis, or a combination thereof into cells and/or the bloodstream while concurrently maintaining chemical activity of the antioxidants. In certain aspects, these formulations include emulsions and balms each having a lipophilic carrier and a lipophilic antioxidant solubilized by the lipophilic carrier. Also disclosed herein are methods for making these compositions for topical application.
Abstract: A highly efficient, Z-selective ring-closing metathesis system for the formation of macrocycles using a stereoretentive, ruthenium-based catalyst supported by a dithiolate ligand is reported. This catalyst is demonstrated to be remarkably active as observed in initiation experiments showing complete catalyst initiation at ?20° C. within 10 min. Using easily accessible diene starting materials bearing a Z-olefin moiety, macrocyclization reactions generated products with significantly higher Z-selectivity in appreciably shorter reaction times, in higher yield, and with much lower catalyst loadings than in previously reported systems. Macrocyclic lactones ranging in size from twelve-membered to seventeen-membered rings are synthesized in moderate to high yields (68-79% yield) with excellent Z-selectivity (95%-99% Z).
Abstract: The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.
Type:
Grant
Filed:
April 26, 2021
Date of Patent:
November 7, 2023
Assignee:
Artax Biopharma Inc.
Inventors:
Julio Castro, Andrés Gagete Mateos, Peter J. Machin, Christopher Loren Vandeusen
Abstract: The present invention relates to a method for the synthesis of 2,5-furandicarboxylic acid, and more specifically, the present invention relates to a more efficient and economical method capable of preparing 2,5-furandicarboxylic acid having various functions with high purity and high yield, even without using a transition metal catalyst.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
October 24, 2023
Assignees:
SAMYANG CORPORATION, RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
Inventors:
Chun Rim Oh, Deuk Rak Lee, Won Jung Lee, Chi Wan Lee, Ji Eun Choi, Young Sug Kim, Jung Woon Yang, Tae Woo Lee
Abstract: Processes for preparing epoxide compounds are provided. Processes for using epoxide compounds and their industrial applications are also provided.
Type:
Grant
Filed:
June 3, 2022
Date of Patent:
October 24, 2023
Assignee:
ZSCHIMMER & SCHWARZ, INC.
Inventors:
Antonio Leyva Pérez, Judit Oliver Meseguer, Susi Hervàs Arnandis, Douglas G. Placek
Abstract: A process for preparing 5-(alkoxycarbonyl)furan-2-carboxylic acids (ACFC) by oxidizing various furcates in the presence of a catalyst containing cobalt, manganese, and bromine, and a solvent while simultaneously removing water vapor from the reaction chamber. The process can produce ACFC with high purity and low color, and in high yield.
Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
Type:
Grant
Filed:
August 20, 2021
Date of Patent:
October 17, 2023
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Abstract: This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
Type:
Grant
Filed:
September 16, 2022
Date of Patent:
October 17, 2023
Assignee:
BECKLEY PSYTECH LIMITED
Inventors:
Massimo Muratore, Amir Lotfi Moghaddam, Christopher Wong
Abstract: There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of triple negative breast cancer (TNBC) to a patient in need thereof.
Abstract: The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected from the group consisting of choline, N-methylaminoethanol, 2-amino-2-methylpropanol and 2-dimethylaminoethanol.
Type:
Grant
Filed:
October 31, 2019
Date of Patent:
October 17, 2023
Assignee:
APROFOL AG
Inventors:
Martin Ulmann, Gerd Wiesler, Arthur Bodenmüller, Markus Müller
Abstract: The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.
Type:
Grant
Filed:
July 14, 2022
Date of Patent:
October 10, 2023
Assignee:
Zelira Therapeutics Operations Pty Ltd
Inventors:
Harry Karelis, Mara Gordon, Stewart Smith, Stewart Washer
Abstract: A catalyst support comprising at least 95% silicon carbide, having surface areas of ?10 m2/g and pore volumes of ?1 cc/g. A method of producing a catalyst support, the method including mixing SiC particles of 0.1-20 microns, SiO2 and carbonaceous materials to form an extrusion, under inert atmospheres, heating the extrusion at temperatures of greater than 1400° C., and removing residual carbon from the heated support under temperatures below 1000° C. A catalyst on a carrier, comprising a carrier support having at least about 95% SiC, with a silver solution impregnated thereon comprising silver oxide, ethylenediamine, oxalic acid, monoethanolamine and cesium hydroxide. A process for oxidation reactions (e.g., for the production of ethylene oxide, or oxidation reactions using propane or methane), or for endothermic reactions (e.g., dehydrogenation of paraffins, of ethyl benzene, or cracking and hydrocracking hydrocarbons).